{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:51:20Z","timestamp":1789419080192,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2022J011461"],"award-info":[{"award-number":["2022J011461"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.gene.2025.149369","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T16:11:53Z","timestamp":1740586313000},"page":"149369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Epigenetic activation of PTEN by valproic acid inhibits PI3K\/AKT signaling and Burkitt lymphoma cell growth"],"prefix":"10.1016","volume":"950","author":[{"given":"Chuntuan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengquan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8928-7944","authenticated-orcid":false,"given":"Jingjing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunyi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanlin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuopeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2025.149369_b0005","doi-asserted-by":"crossref","unstructured":"Al-Bloushy, Randa Ibrahim, Salma Hani Sait and Ali H. Algiraigri. 2020. Valproic acid for the treatment of refractory pediatric primary bone anaplastic large-cell lymphoma: A case report and literature review. J. Appl. Hematol. 11: 77 - 79. DOI:10.4103\/joah.joah_3_20.","DOI":"10.4103\/joah.joah_3_20"},{"issue":"6","key":"10.1016\/j.gene.2025.149369_b0010","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1111\/bjh.19425","article-title":"Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation","volume":"204","author":"Atallah-Yunes","year":"2024","journal-title":"Br. J. Haematol."},{"issue":"Suppl 1","key":"10.1016\/j.gene.2025.149369_b0015","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.clml.2011.03.029","article-title":"Non-Hodgkin's lymphoma: the old and the new","volume":"11","author":"Cabanillas","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"2","key":"10.1016\/j.gene.2025.149369_b0020","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1756-8722-2-22","article-title":"New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer","volume":"1","author":"Cang","year":"2009","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.gene.2025.149369_b0025","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1182\/blood.2019004099","article-title":"The treatment of Burkitt lymphoma in adults","volume":"137","author":"Crombie","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.gene.2025.149369_b0030","doi-asserted-by":"crossref","unstructured":"de Armas-Castellano A, Infante-Ventura D, Del Pino-Sede\u00f1o T, Hern\u00e1ndez YG, Quiros R, Le\u00f3n-Salas B, Ribrag V, Trujillo-Mart\u00edn MM; ERN EuroBlood Working Group. 2025. Prognostic Factors for Survival in Adults With Burkitt Lymphoma: A Systematic Review. Cancer Med. Feb;14(3):e70513. doi: 10.1002\/cam4.70513. PMID: 39878399; PMCID: PMC11775923.","DOI":"10.1002\/cam4.70513"},{"issue":"S1","key":"10.1016\/j.gene.2025.149369_b0035","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1017\/S0266462324001818","article-title":"PP08 Prognostic factors for survival in adults with Burkitt Lymphoma: a systematic review and meta-analysis","volume":"40","author":"De Armas-Castellano","year":"2024","journal-title":"Int. J. Technol. Assess. Health Care."},{"issue":"1","key":"10.1016\/j.gene.2025.149369_b0040","doi-asserted-by":"crossref","first-page":"7995","DOI":"10.1080\/21655979.2021.1977557","article-title":"Transcription factor 3 (TCF3) combined with histone deacetylase 3 (HDAC3) down-regulates microRNA-101 to promote Burkitt lymphoma cell proliferation and inhibit apoptosis","volume":"12","author":"Dong","year":"2021","journal-title":"Bioengineered."},{"issue":"9","key":"10.1016\/j.gene.2025.149369_b0045","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.gene.2025.149369_b0050","first-page":"773","article-title":"Valproic Acid Enhances the Anti-tumor Effect of (-)-gossypol to Burkitt Lymphoma Namalwa Cells","volume":"28","author":"Gong","year":"2015","journal-title":"Biomed. Environ. Sci."},{"issue":"11","key":"10.1016\/j.gene.2025.149369_b0055","article-title":"Characterization of Histone Deacetylase Mechanisms in Cancer Development","volume":"29","author":"Hai","year":"2021","journal-title":"Front Oncol."},{"issue":"10","key":"10.1016\/j.gene.2025.149369_b0060","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cellsig.2011.05.004","article-title":"Akt signalling in health and disease","volume":"23","author":"Hers","year":"2011","journal-title":"Cell Signal."},{"key":"10.1016\/j.gene.2025.149369_b0065","doi-asserted-by":"crossref","unstructured":"Imai Y, Maru Y, Tanaka J. 2016. Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies. Cancer Sci. ;107(11):1543-1549. doi: 10.1111\/cas.13062. Epub 2016 Nov 4. PMID: 27554046; PMCID: PMC5132279.","DOI":"10.1111\/cas.13062"},{"key":"10.1016\/j.gene.2025.149369_b0070","unstructured":"Li C, Xu Y, Xin P, Zheng Y, Zhu X. 2020. Role and mechanism of PTEN in Burkitt's lymphoma. Oncol Rep. 2020 Feb;43(2):481-490. doi: 10.3892\/or.2020.7457. Epub 2020 Jan 9. PMID: 31922234; PMCID: PMC6967105."},{"issue":"15","key":"10.1016\/j.gene.2025.149369_b0075","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12935-015-0213-1","article-title":"The dual PI3K\/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells","volume":"24","author":"Li","year":"2015","journal-title":"Cancer Cell Int."},{"issue":"329","key":"10.1016\/j.gene.2025.149369_b0080","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bbr.2017.04.015","article-title":"Antidepressant-like effect of valproic acid-Possible involvement of PI3K\/Akt\/mTOR pathway","volume":"30","author":"Lima","year":"2017","journal-title":"Behav Brain Res."},{"issue":"1","key":"10.1016\/j.gene.2025.149369_b0085","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bbapap.2007.10.003","article-title":"Targeting phosphoinositide 3-kinase: moving towards therapy","volume":"1784","author":"Marone","year":"2008","journal-title":"Biochim. Biophys. Acta."},{"issue":"6","key":"10.1016\/j.gene.2025.149369_b0090","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2559.2009.03290.x","article-title":"Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas","volume":"54","author":"Marquard","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.gene.2025.149369_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108114","article-title":"The contributory roles of histone deacetylases (HDACs) in hematopoiesis regulation and possibilities for pharmacologic interventions in hematologic malignancies","volume":"100","author":"Mehrpouri","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.gene.2025.149369_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2020.105734","article-title":"Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance","volume":"122","author":"Mosleh","year":"2020","journal-title":"Int. J. Biochem. Cell. Biol."},{"issue":"10","key":"10.1016\/j.gene.2025.149369_b0105","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic Acid and Epilepsy: From Molecular Mechanisms to Clinical Evidences","volume":"17","author":"Romoli","year":"2019","journal-title":"Curr. Neuropharmacol."},{"issue":"1","key":"10.1016\/j.gene.2025.149369_b0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.exphem.2004.09.008","article-title":"Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines","volume":"33","author":"Sakajiri","year":"2005","journal-title":"Exp. Hematol."},{"issue":"11","key":"10.1016\/j.gene.2025.149369_b0115","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/cancers11111794","article-title":"HDAC Inhibitors in Acute Myeloid Leukemia","volume":"11","author":"San Jos\u00e9-En\u00e9riz","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.gene.2025.149369_b0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/bs.pmbts.2023.02.011","article-title":"Histone deacetylase (HDACs) inhibitors: Clinical applications","volume":"198","author":"Shanmukha","year":"2023","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"issue":"6","key":"10.1016\/j.gene.2025.149369_b0125","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/nu10060731","article-title":"Targeting histone deacetylases with natural and synthetic agents: an emerging anticancer strategy","volume":"10","author":"Singh","year":"2018","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.gene.2025.149369_b0130","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/febs.15122","article-title":"Valproic acid targets HDAC1\/2 and HDAC1\/PTEN\/Akt signalling to inhibit cell proliferation via the induction of autophagy in gastric cancer","volume":"287","author":"Sun","year":"2020","journal-title":"FEBS J."},{"key":"10.1016\/j.gene.2025.149369_b0135","doi-asserted-by":"crossref","unstructured":"Wang X, Waschke BC, Woolaver RA, Chen SMY, Chen Z, Wang JH. 2020. HDAC inhibitors overcome immunotherapy resistance in B-cell lymphoma. Protein Cell. Jul;11(7):472-482. doi: 10.1007\/s13238-020-00694-x. Epub 2020 Mar 11. PMID: 32162275; PMCID: PMC7305292.","DOI":"10.1007\/s13238-020-00694-x"},{"key":"10.1016\/j.gene.2025.149369_b0140","doi-asserted-by":"crossref","unstructured":"West AC, Johnstone RW. 2014. New and emerging HDAC inhibitors for cancer treatment. J. Clin. Invest. 2014 Jan;124(1):30-9. doi: 10.1172\/JCI69738. Epub 2014 Jan 2. PMID: 24382387; PMCID: PMC3871231.","DOI":"10.1172\/JCI69738"},{"key":"10.1016\/j.gene.2025.149369_b0145","doi-asserted-by":"crossref","unstructured":"Yang FF, Hu T, Liu JQ, Yu XQ, Ma LY. 2023. Histone deacetylases (HDACs) as the promising immunotherapeutic targets for hematologic cancer treatment. Eur. J. Med. Chem. Jan 5;245(Pt 2):114920. doi: 10.1016\/j.ejmech.2022.114920. Epub 2022 Nov 13. PMID: 36399875.","DOI":"10.1016\/j.ejmech.2022.114920"},{"issue":"1","key":"10.1016\/j.gene.2025.149369_b0150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10495-013-0906-7","article-title":"Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells","volume":"19","author":"Yoon","year":"2014","journal-title":"Apoptosis"},{"issue":"6","key":"10.1016\/j.gene.2025.149369_b0155","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1080\/10428190701344907","article-title":"Valproic acid monotherapy leads to CR in a patient with refractory diffuse large B cell lymphoma","volume":"48","author":"Zain","year":"2007","journal-title":"Leuk Lymphoma."}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037811192500157X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S037811192500157X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T09:13:29Z","timestamp":1741684409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S037811192500157X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":31,"alternative-id":["S037811192500157X"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2025.149369","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic activation of PTEN by valproic acid inhibits PI3K\/AKT signaling and Burkitt lymphoma cell growth","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2025.149369","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"149369"}}